Clinical trial · Observational
Blood Test to Measure DNA Damage in Blood
Gamma-H2AX as a Molecular Predictor of Prostate Cancer Radiosensitivity
NCT00523471CI-TRIAL-00021163terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To check the radiosensitivity level in individual patients based on their DNA damage level.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood test | Procedure | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * prostate cancer diagnosis * undergoing radiotherapy * agree to participate in study Exclusion Criteria: * not willing to participate * not undergoing radiotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.